Join the club for FREE to access the whole archive and other member benefits.

Cellvie

Cellvie develops cell-derived medicines, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell

Cellvie is the leader in Therapeutic Mitochondria Transplantation (TMT).

The team is seeking to bring about a novel treatment modality, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell.

Therapeutic Mitochondria Transplantation, an approach for mitochondria augmentation and replacement, was developed by Dr. James McCully at Harvard Medical School. cellvie was founded to take this technology from bench to bed, starting in heart attacks and solid organ transplantation.

Visit website: https://cellvie.bio

 cellvie

Details last updated 16-Sep-2022

People at Cellvie

Alex Schueller

Founder and CEO at Cellvie

Cellvie News

cellvie closes $5.5 million of financing to develop its allogeneic mitochondria therapies

KIZOO Technology Ventures - 06-Feb-2023

Mitochondria dysfunction is linked to several ageing-related diseases, including neurodegeneration, so a big potential market

Read more...

Reason reports back from October's Rejuvenation Startup Summit

Fight Aging! - 19-Oct-2022

Some really exciting developments with quite a few in clinical trials

Read more...

Longevity Technology interviews cellvie CEO, Alex Schueller, about therapeutic mitochondria

Longevity Technology - 14-Sep-2022

Initially targeting ischemia-reperfusion injury, TMT has potential to treat multiple age-related diseases

Read more...
Topics mentioned on this page:
Mitochondria